Evolocumab Lowers LDL in Statin-Intolerant Patients

January 23, 2014

THOUSAND OAKS, CA — Treating statin-intolerant patients with evolocumab (Amgen, Thousand Oaks, CA) significantly lowers LDL-cholesterol levels, according to the top-line results of the GAUSS-2 study announced today[1].

Evolocumab is an investigational human monoclonal antibody for proprotein convertase subtilisin-kexin type 9 (PCSK9). The company said the study met both co–primary end points, including the percent reduction from baseline in LDL-cholesterol levels at week 12 and the mean percent reduction from baseline in LDL-cholesterol levels at weeks 10 and 12.

The study included 307 patients who were unable to tolerate at least two different statins because of muscle-related side effects. Patients were randomized to one of four treatment groups: subcutaneous injection of evolocumab 140 mg every two weeks plus oral placebo; subcutaneous injection of evolocumab 420 mg once monthly plus oral placebo; subcutaneous placebo every two weeks plus oral ezetimibe (Zetia, Merck) 10 mg daily; or subcutaneous placebo monthly plus oral ezetimibe 10 mg daily.

The mean percent reductions observed with evolocumab were statistically significant at both doses when compared with the placebo- and ezetimibe-treated patients.

In terms of side effects, 7.8% of patients in the evolocumab arm reported headaches, as did 8.8% in the ezetimibe arm. Myalgia was observed in 7.8% of the evolocumab patients and in 17.6% of those treated with ezetimibe. Just over 6% of patients treated with the novel PCSK9 inhibitor reported pain in their extremities or muscle spasms.

Amgen recently reported positive top-line results with evolocumab in MENDEL-2 and DESCARTES . In MENDEL-2, patients had LDL-cholesterol levels ranging from 100 mg/dL to 189 mg/dL and were not receiving drug therapy. In DESCARTES, individuals with hyperlipidemia received evolocumab on top of background lipid-lowering treatment, including ezetimibe and high-dose atorvastatin.

Amgen plans to review the GAUSS-2 data and submit the results for presentation at a cardiology conference and for publication.

As reported by heartwire , monoclonal antibodies are a busy research area, with several pharmaceutical companies developing drugs. Pfizer and Sanofi/Regeneron are also working on PCSK9 inhibitors, which are in various stages of development and in general have shown LDL-lowering prowess similar to evolocumab. Sanofi and Regeneron announced today that they are collaborating with the American College of Cardiology (ACC) in a manner that will help identify eligible patients for the upcoming phase 3 ODYSSEY OUTCOMES trial with alirocumab. The ACC will identify candidates for PSCK9 treatment through its PINNACLE registry. It is the first time the registry will be used for clinical-trial recruitment.

Amgen sponsored the GAUSS-2 trial.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.